References
- Ishizuka T, Fujimori I, Kato M, Noji-Sakikawa C, Saito M, Yoshigae Y, Kubota K, Kurihara A, Izumi T, Ikeda T, Okazaki O. (2010). Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. J Biol Chem 285:11892–11902.
- Kohara Y, Kubo K, Imamiya E, Wada T, Inada Y, Naka T. (1996). Synthesis and angiotensin II receptor antagonistic activities of benzimidazole derivatives bearing acidic heterocycles as novel tetrazole bioisosteres. J Med Chem 39:5228–5235.
- Kondo T, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. (1996a). Disposition of the new angiotensin II receptor antagonist candesartan cilexetil in rats and dogs. Arzneimittelforschung 46:594–600.
- Kondo T, Hagiwara K, Kato Y, Yoshida K, Yoshimura Y, Motohashi M, Tanayama S. (1996b). Metabolic fate of TCV-116, a new angiotensin II receptor antagonist, in rats and dogs. Jpn Pharmacol Ther 24:S915.
- Kubo K, Kohara Y, Yoshimura Y, Inada Y, Shibouta Y, Furukawa Y, Kato T, Nishikawa K, Naka T. (1993). Nonpeptide angiotensin II receptor antagonists. Synthesis and biological activity of potential prodrugs of benzimidazole-7-carboxylic acids. J Med Chem 36:2343–2349.
- Kusumoto K, Igata H, Ojima M, Tsuboi A, Imanishi M, Yamaguchi F, Sakamoto H, Kuroita T, Kawaguchi N, Nishigaki N, Nagaya H. (2011). Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models. Eur J Pharmacol 669:84–93.
- Ma SF, Anraku M, Iwao Y, Yamasaki K, Kragh-Hansen U, Yamaotsu N, Hirono S, Ikeda T, Otagiri M. (2005). Hydrolysis of angiotensin II receptor blocker prodrug olmesartan medoxomil by human serum albumin and identification of its catalytic active sites. Drug Metab Dispos 33:1911–1919.
- Masungi C, Borremans C, Willems B, Mensch J, Van Dijck A, Augustijns P, Brewster ME, Noppe M. (2004). Usefulness of a novel Caco-2 cell perfusion system. I. In vitro prediction of the absorption potential of passively diffused compounds. J Pharm Sci 93:2507–2521.
- Miret S, Abrahamse L, de Groene EM. (2004). Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa. J Biomol Screen 9:598–606.
- Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, Nagaya H. (2011). In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther 336:801–808.
- Sankyo Co., Ltd. (2001). 2.9. In vitro hydrolysis of olmesartan medoxomil and RNH-8097 in liver and intestine of rat (Report #GR 146-072). Vol.6. FDA (US) NDA #21, 286: Pharmacology Review(s) 48–49. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21–286_Benicar_pharmr_P2.pdf. Accessed on: 27 December 2011.
- Skolnik S, Lin X, Wang J, Chen XH, He T, Zhang B. (2010). Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay. J Pharm Sci 99:3246–3265.
- Sun H, Chow EC, Liu S, Du Y, Pang KS. (2008). The Caco-2 cell monolayer: Usefulness and limitations. Expert Opin Drug Metab Toxicol 4:395–411.